期刊文献+

N端脑钠肽前体在川崎病患儿中的变化及意义 被引量:3

Change and significance of NT-proBNP in children with Kawasaki disease
下载PDF
导出
摘要 目的探讨N末端脑利钠肽前体(N-terminal pro-brain natriuretic peptide,NT-proBNP)在川崎病(Kawasaki disease,KD)患儿中的变化及其临床意义。方法分别测定46例确诊为KD急性期的患儿血浆NT-proBNP水平,并测定了其应用IVIG后患儿血浆NT-proBNP水平,同时以15例小儿上呼吸道感染作为对照组,并检测其血浆NT-proBNP水平。分别测定KD患儿在急性期及恢复期的外周血白细胞计数、C反应蛋白及血浆心肌肌钙蛋白(cardiac troponin I,cTnI)水平,常规超声心动图检测血流及冠状动脉病变情况。结果 KD患儿急性期血NT-proBNP水平为(701.4±94.8)ng/L,而对照组小儿血浆中NT-proBNP水平为(58.9±15.1)ng/L,两组相比差异具有统计学意义(P=0.001)。KD病人血浆NT-proBNP应用IVIG前明显高于应用IVIG后,检测结果提示NT-proBNP水平与急性期患儿的心肌肌钙蛋白水平有关。结论血浆NT-proBNP水平在KD急性期显著升高,而在疾病恢复期其水平明显降低。KD患儿急性期血浆NT-proBNP水平的升高可能与急性期KD患儿的心肌炎症及炎性因子的升高有关。 Ojective To examine the value of NT-pro BNP in the diagnosis of KD and to explore the mechanism of the change in plasma NT-pro BNP in children with KD.Methods Forty-six patients,aged from 4 months to 75 months,with KD were enrolled and fifteen patients with acute upper respiratory infection were used as controls.Blood sample was obtained to measure plasma NT-pro BNP concentrations in the acute and convalescent phases of KD and in the acute phase of the control patients.Plasma NT-pro BNP was measured using enzyme immunoassay.Other laboratory data including complete blood cell count,C-reactive protein,ESR,etc,were also measured in acute phase in both groups.The serum cardiac troponin I was also detected in acute phase of children with KD.Two dimensional echocardiography was performed to check for coronary lesions of patients with KD.The correlation between plasma NT-pro BNP and the above parameters was analyzed.Results The mean plasma NT-pro BNP concentration in patients with KD in the acute phase was(701.4±94.8) ng/L,and it was(58.9 ±15.1) ng/L in patients of control group.The plasma NT-pro BNP in patients with KD in the acute phase was significantly higher than that of the control group(P=0.001).In 46 cases of KD,the plasma NT-pro BNP concentrations were measured both in Pre-IVIG and Post-IVIG.The mean plasma NT-pro BNP concentration of KD in Pre-IVIG was(701.4±94.8) ng/L and it was(164±35) ng/L in Post-IVIG.Serum cTnI has the same change the control group.Conclusion The plasma NT-pro BNP concentration increased in the acute phase and decreased significantly in the convalescent phase of KD.The plasma NT-pro BNP might be one of the useful biological markers of KD,and the mechanism of change in plasma NT-pro BNP in KD might be associated with cardiac injury and inflammatory factors.
出处 《江西医药》 CAS 2010年第10期973-975,共3页 Jiangxi Medical Journal
关键词 皮肤黏膜淋巴结综合征 脑钠肽 N端一脑钠肽前体 mucocutaneous lymph node syndrome natriuretie peptide brain N-terminal-pro-B-type Natriuretie peptide
  • 相关文献

参考文献15

  • 1Witt MT,Minich LL,Bohnsack JF,et al.Kawasaki disease:more patients are being diagnosed who do not meet American Heart Asso-ciation criteria.Pediatrics,1999,104:e10.
  • 2王琍,林毅,苏英姿,汪芸,赵地,吴铁吉.283例川崎病的临床分析[J].中华儿科杂志,2004,42(8):609-612. 被引量:84
  • 3Kawamura T,Wago M,Kawaguchi H,et al.Plasma brain natriuret-ic peptide concentrations in patients with Kawasaki disease.Pediatr Int,2000,42:241.
  • 4Kawasamura T.Acute febrile mucocutaneous syndrome.Jpn J Allergy,16:178.
  • 5Ayuswa M,Sonobe T,Uemura S,et al.Revision of diagnosticguide-lines for Kawasaki disease(the 5th revised edition).Pediatr Int,2005,47:232.
  • 6Newburger JW,Takahashi M,Gerber MA,et al.Diagnosis,treatment,and long-term management of Kawasaki disease:astatement for health professionals from the committee on rheumatic fever,Endo-carditis and kawasaki disease,council on cardiovascular disease in the young,American Heart Association.Circulation,2004,110:2747.
  • 7Burns JC,Mason WH,Glode MP,et al.Newburger JW(1991)Clinical and epidemiologic characterisics of patients referred for evaluation of possible Kawasaki disease,United states Muiticenter Kawasaki dis-ease Study Group.J Pediatr,118(5):680.
  • 8吴瑞萍,胡亚美,江载芳,主编.实用儿科学.上册.第6 版.北京:人民卫生出版社.2002.687.
  • 9Mir TS,Marohn S,Laer S,et al.Plasma concentrations of N-termi-nal pro-brain natriurtic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure.Pediatrics,2002,110:e76.
  • 10武育蓉,陈树宝,黄美蓉,张玉奇,孙锟,陈笋.氨基末端脑利钠肽前体在室间隔缺损合并心力衰竭诊断中的价值[J].中华儿科杂志,2005,43(3):161-164. 被引量:37

二级参考文献32

  • 1王琍,林毅,苏英姿,汪芸,赵地,吴铁吉.283例川崎病的临床分析[J].中华儿科杂志,2004,42(8):609-612. 被引量:84
  • 2武育蓉,陈树宝,黄美蓉,张玉奇,孙锟,陈笋.氨基末端脑利钠肽前体在室间隔缺损合并心力衰竭诊断中的价值[J].中华儿科杂志,2005,43(3):161-164. 被引量:37
  • 3姚渭清,陈树宝,周爱卿,王荣发,孙锟,黄美蓉,邓杏飞,高伟.室间隔缺损合并心力衰竭的机理研究[J].中华儿科杂志,1994,32(3):139-141. 被引量:23
  • 4Mir TS, Marohn S, Laer S,et al. Plasma concentrations of N-terminal pro-brain natriurtic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure.Pediatrics,2002,110:e76.
  • 5Kawai K,Hata K,Takaoka H,et al. Plasma brain natriuretic peptide as a noval therapetic indicator in idiopathic dilated cardiomyopathy during β-blocker therapy: a potential of hormone-guided treatment.Am Heart J,2001,141:925-932.
  • 6Grzybowski J,Bilinska ZT,Janas J,et al. Plasma concentrations of N-terminal brain natriuretic peptide are raised in asymptomatic relatives of dilatec cardiomyopathy patients with left ventricular enlargement.Heart,2002,88:191-192.
  • 7Suneel T,Downie P,Davies J,et al. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis.Eur J Heart Fail,2001,3:15-19.
  • 8Kinnunen P,Vuolteenaho O,Ruskoaho H,et al. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium:effect of stretching.Endocrinology,1993,132:1961-1970.
  • 9Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int,2003,45:249-254.
  • 10Colann SD,Borow KM,Neumann A. Left ventricular end-systolic wall stress-velocity of fiber shortening relation:a load-independent index of myocardial contractility.J Am Coll Cardiol,1984,4:715-721.

共引文献136

同被引文献36

  • 1Yanagawa H,Nakamura Y,Yashiro M. Incidence survey of Kawasaki disease in 1997 and 1998 in Japan[J].Pediatrics,2001,(03):E33.
  • 2Alexoudi I,Kanakis M,Kapsimali V. Kawasaki disease:current aspects on etiopathogenesis and therapeutic management[J].Autoimmunity Reviews,2011,(09):544-547.
  • 3胡亚美;江载芳.褚福棠实用儿科学[M]北京:人民卫生出版社,2002698-705.
  • 4Group JCSJR. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease[J].Pediatrics International,2005,(06):711-732.
  • 5Kim DS. Kawasaki disease[J].Yonsei Medical Journal,2006,(06):759-772.
  • 6Kobayashi T,Inoue Y,Takeuchi K. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease[J].Circulation,2006,(22):2606-2612.
  • 7Anderson MS,Todd JK,Glode MP. Delayed diagnosis of Kawasaki syndrome:an analysis of the problem[J].Pediatrics,2005,(04):e428-e433.
  • 8Ayusawa M,Sonobe T,Uemura S. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition)[J].Pediatrics International,2005,(02):232-234.
  • 9Huang FY,Chang TY,Chen MR. The -590 C/T and 8375 A/G interleukin-4 polymorphisms are not associated with Kawasaki disease in Taiwan Residents children[J].Human Immunology,2008,(01):52-57.
  • 10Newburger JW,Takahashi M,Gerber MA. Diagnosis,treatment,and long-term management of Kawasaki disease:a statement for health professionals from the Committee on Rheumatic Fever,Endocarditis and Kawasaki Disease,Council on Cardiovascular Disease in the Young,American Heart Association[J].Circulation,2004,(17):2747-2771.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部